Last reviewed · How we verify
Non-active placebo control
A non-active placebo control contains no pharmacologically active ingredients and serves as a comparator in clinical trials to establish baseline efficacy and safety.
A non-active placebo control contains no pharmacologically active ingredients and serves as a comparator in clinical trials to establish baseline efficacy and safety. Used for Clinical trial control comparator (non-therapeutic use).
At a glance
| Generic name | Non-active placebo control |
|---|---|
| Sponsor | The Center for Clinical and Cosmetic Research |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Placebo controls are inert formulations used in randomized controlled trials to distinguish the true therapeutic effect of an investigational drug from placebo response, natural disease progression, and observer bias. They allow researchers to measure the magnitude of clinical benefit attributable to the active drug rather than expectation or other non-specific factors.
Approved indications
- Clinical trial control comparator (non-therapeutic use)
Common side effects
- Placebo response (symptom improvement without active drug)
Key clinical trials
- The Effect of NP-2006 on Sleep Quality and Health (NA)
- Effects of Positive Psychological Group Psychotherapy and Auricular Acupressure on Withdrawal Symptoms (NA)
- Effectiveness of Combined Super Inductive System (SIS) Therapy With Therapeutic Exercise and Health Education in Lateral Elbow Tendinopathy (NA)
- A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2 (PHASE3)
- A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062) (PHASE2, PHASE3)
- A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 ) (PHASE3)
- MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF) (PHASE2)
- In-Bedroom Renewed Air as Anti-inflammatory Adjuvant Therapy in Cancer Survivors (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Non-active placebo control CI brief — competitive landscape report
- Non-active placebo control updates RSS · CI watch RSS
- The Center for Clinical and Cosmetic Research portfolio CI